



The Henry Schueler 41 & 9 Foundation

Second International Forum for Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

AGENDA

Dates: November 7th and 8th, 2019

Location: Palmer House, 17 East Monroe Street, Chicago, Illinois 60603

Co-Chairs:

Thomas J. Walsh, MD, PhD (hon), FIDSA, FAAM, FCCP, FECMM, FAAAS

Founding Director, Transplantation-Oncology Infectious Diseases Program

Chief, Infectious Diseases Translational Research Laboratory

Professor of Medicine, Pediatrics, and Microbiology & Immunology

Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital

Henry Schueler 41 & 9 Foundation Scholar in Mucormycosis

Adjunct Professor of Pathology, The Johns Hopkins University School of Medicine

Adjunct Professor of Medicine, University of Maryland School of Medicine

Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM, FAAAS

Texas 4000 Distinguished Endowed Professor For Cancer Research

Deputy Head, Division of Internal Medicine

The University of Texas MD Anderson Cancer Center

Adjunct Professor Baylor College of Medicine

Adjunct Professor University of Houston

Objectives:

1. To review the advances in understanding of the epidemiology, genomics, pathogenesis, and host defenses of the Mucorales and mucormycosis
2. To discuss the advances made in diagnosis and treatment of mucormycosis
3. To develop new objectives for improving the outcome of patients with mucormycosis
4. To formulate a path for an updated publication supplement to the 2012 publication of [Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis](#) (Clin Infect Dis. 54 Suppl 1:S1-4; 2012)

“Dad, stay strong. We are going to beat this thing.” – Henry “Hank” Schueler, Age 14, 2007.



The Henry Schueler 41 & 9 Foundation

Second International Forum for Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

AGENDA

Day 1: Thursday, November 7, 2019

Epidemiology of Mucormycosis: Lessons Learned During the Past 5 Years

9:00 a.m. – Welcome & Origins, Mission, & Achievements of The Henry Schueler 41 & 9 Foundation

Speaker: Matthew Schueler, Henry Schueler 41 & 9 Foundation

9:15 a.m. – Introduction to the Second Henry Schueler 41 & 9 Foundation Forum for Mucormycosis & Objectives

Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, NY, USA

9:30 a.m. – History of Mucormycosis

Speaker: George Petrikos, European University Crete, Crete, Greece

10:00 a.m. - Who is at risk for infection and what are the outcomes?

Speaker: Olivier Lortholary, Institute Pasteur, Paris, France

10:30 a.m. - Trauma-related Mucormycosis: The Winds of War and Their Mycological Consequences

Speaker: Duane Hospenthal, University of Texas San Antonio, San Antonio, Texas, USA

11:00 a.m. – 15 Minute break

11:15 a.m. – Hospital Acquired Mucormycosis: In Search of the Environmental Sources of Infection

Speaker: M. Hong Nguyen, University of Pittsburgh, Pittsburgh, PA, USA

11:45 a.m. – Epidemiology of Pediatric Mucormycosis: Small Patients with Great Challenges

Speaker: Emmanuel Roilides, Aristotle University, Thessaloniki, Greece

12:15 p.m. – Roundtable on Epidemiology of Mucormycosis

12:45 p.m. – Lunch Break

Pathogenesis and Host Defenses

2:00 p.m. – Advances in Understanding the Pathogenesis of Mucormycosis

Speaker: Ashraf Ibrahim, UCLA, Los Angeles, CA, USA

“Dad, stay strong. We are going to beat this thing.” – Henry “Hank” Schueler, Age 14, 2007.



The Henry Schueler 41 & 9 Foundation Second International Forum for Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

AGENDA

2:30 p.m. – Insights into Pathogenesis of Mucormycosis from Invertebrate Models
Speaker: *Dimitrios Kontoyiannis, MDACC, Houston, TX, USA*

3:00 p.m. – Innate Host Defenses against Mucorales
Speaker: *George Chamilos, University of Crete, Crete, Greece*

3:30 p.m. – 15 Minute Break

3:45 p.m. – Roundtable on Pathogenesis of Mucormycosis

4:45 p.m. – Summary for the day
Speaker: *Dimitrios P. Kontoyiannis*

6:00 p.m. – Dinner

Day 2: Friday, November 8, 2019

Clinical and Laboratory Diagnosis: Pathways to Early Recognition, Preemptive Intervention, and Improved Outcome

8:00 a.m. – Assessment of Mucormycosis in Adult Patients
Speaker: *Olivier Lortholary, Institute Pasteur, Paris, France*

8:30 a.m. – Assessment of Mucormycosis in Pediatric Patients
Speaker: *Emmanuel Roilides, Aristotle University, Thessaloniki, Greece*

9:00 a.m. – Clinical Laboratory Diagnosis of Mucormycosis: What are the Standards and How Can They be Improved

9:30 a.m. – From Pathogenesis to Molecular Diagnosis of Mucormycosis
Speaker: *Ashraf Ibrahim, UCLA, Los Angeles, CA, USA*

10:00 a.m. – 15 Minute Break

10:15 a.m. – Developing laboratory diagnostic tools: bring advances from bench to bedside
Speaker: *Thomas J. Walsh, Weill Cornell Medicine, New York, NY US*

“Dad, stay strong. We are going to beat this thing.” – Henry “Hank” Schueler, Age 14, 2007.



The Henry Schueler 41 & 9 Foundation

Second International Forum for Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

AGENDA

10:45 a.m. – Roundtable Discussion on Diagnosis of Mucormycosis

11:45 a.m. – Lunch

Treatment and Outcome

12:45 p.m. – Antifungal Pharmacology and Treatment of Mucormycosis

Speaker: Russel Lewis, University of Bologna, Bologna, Italy

1:15 p.m. – Liposomal Amphotericin B for Treatment of Mucormycosis

Speaker: Andreas Groll, University Children's Hospital in Münster, Germany

1:45 p.m. – Amphotericin B Lipid Complex for Treatment of Mucormycosis

Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, New York, USA

2:15 p.m. – 15 Minute Break

2:30 p.m. – Isavuconazole for Treatment of Mucormycosis

Speaker: Kate Mullane, University of Chicago, Chicago, IL, USA

3:00 p.m. – Investigational Agents for Treatment of Mucormycosis

Speaker: Matthew McCarthy, Weill Cornell Medicine, New York, NY, USA

3:30 p.m. – Combination Antifungal Therapy for Treatment of Mucormycosis

Speaker: Dimitrios P. Kontoyiannis, MDACC, Houston, TX, USA

4:00 p.m. – Adjunctive Therapeutic Modalities: Immune Augmentation and Hyperbaric Oxygen for Treatment of Mucormycosis

Speaker: Emmanuel Roilides, Aristotle University and Hippokration Hospital, Thessaloniki, Greece

4:30 p.m. – Roundtable on Treatment of Mucormycosis

5:15 p.m. – Future Directions

Speaker: Dimitrios P. Kontoyiannis, MDACC, Houston, TX, USA

5:30 p.m. – CID Monograph on Mucormycosis

Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, New York, USA

5:45 p.m. – Final Reflections and Closing

Speaker: Matthew Schueler, Henry Schueler 41 & 9 Foundation

“Dad, stay strong. We are going to beat this thing.” – Henry “Hank” Schueler, Age 14, 2007.